trial

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

NCTId NCT02331433
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 58 (actual)
Sponsored by CoMentis
Primary completion 2015-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
58 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Quadruple
Start
2014-12
Primary completion
2015-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
APN1125

Sponsors

CoMentisLead Sponsor
Alpharmagen, Inc.Collaborator

Investigators

1
David Han, MDPrincipal Investigator

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
58
Phase
PHASE1
Primary Completion Date
2015-11
Status
COMPLETED
relationships
The graph out of here
drug
APN1125
drug
lead_sponsor
CoMentis
company
collaborator
Alpharmagen, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David Han, MD
person